Default company panoramic image

Immunomic Therapeutics, Inc.

Immunomic Therapeutics is a clinical stage biotech company applying proprietary vaccine technology to the $11 billion dollar allergy market.

  • Stage $1M in TTM Revenue
  • Industry Biotechnology
  • Location Hershey, PA, USA
  • Currency USD
  • Founded January 2006
  • Employees 5
  • Website

Company Summary

Immunomic Therapeutics is a clinical stage biotechnology company with exceptional patented science for application to vaccines and vaccine immunotherapy. LAMP-vax™ significantly increases the effectiveness of the immune response while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs are currently being in the clinic in a Phase I study for our allergy vaccine.


  • Default avatar
    William G Hearl
    Chief Executive Officer

    Dr. William Hearl, the founder of ITI, is an experienced and successful scientific businessman and entrepreneur. He worked closely with Johns Hopkins University to capture the LAMP technology and begin operations in 2006. His experience in intellectual property management and business development led to the sub-license of the LAMP technology to Geron Corporation within 30 days of initiating operations. He is also the founder of Capital Genomix.

  • Default avatar
    Bernard C Rudnick
    Chief Financial Officer

    Dr. Mackler’s 27 years of FDA legal/regulatory experience in biomedical products includes biologics, drugs, medical and in vitro diagnostic devices.Bernard C. Rudnick is founder and managing partner of CapGenic Advisors and a member of several angel groups. Mr. Rudnick’s entrepreneurial career includes a number of startups, 3 of which grew to over $60 million in revenue before exiting. He is a founder of one of the nation’s leading entrepreneuri

  • Default avatar
    Bruce F Mackler
    VP of Regulatory and Clinical Affaris

    Dr. Mackler has founded biomedical companies, established and implemented their regulatory strategies and assisted in securing early stage funding. He has advised financial groups on integrated FDA, technical and business issues. These activities integrate his business acumen and academic experience from 15 years as a university/NIH researcher and 27 years in a FDA legal/regulatory practice with premier law firms.

  • Default avatar
    Teri Jones Heiland
    VP of R&D

    Dr. Heiland was one of the founding employees of the Company. She is an experienced molecular biologist and holds multiple patents in the field of genomics. Previously, she led multiple research teams at Capital Genomix, Inc. developing and validating GeneSystem320™ and applying this technology to cancer. She also developed the ImmunoMouse™. Prior, Dr. Heiland was senior scientist at KPL and spent 4 years a project leader.

Previous Investors

  • Default avatar
    Life Sciences Greenhouse of Central Pennsylvania
    Default avatar
    Keiretsu Mid Atlantic and FL
    Default avatar
    MAIN Minority Angel Investment Network